List of Excipients in Branded Drug CHILDRENS IBUPROFEN ORAL SUSPENSION

« Back to Dashboard

Generic Drugs Containing CHILDRENS IBUPROFEN ORAL SUSPENSION

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	ibuprofen	0121-0833	ANHYDROUS CITRIC ACID
PAI Holdings LLC dba PAI Pharma	ibuprofen	0121-0833	CARBOXYMETHYLCELLULOSE SODIUM
PAI Holdings LLC dba PAI Pharma	ibuprofen	0121-0833	CELLULOSE, MICROCRYSTALLINE
PAI Holdings LLC dba PAI Pharma	ibuprofen	0121-0833	GLYCERIN
PAI Holdings LLC dba PAI Pharma	ibuprofen	0121-0833	POLYSORBATE 80

What are the Most Frequently-Used Excipients in CHILDRENS IBUPROFEN ORAL SUSPENSION?

# Of NDCs	Excipient
8	ACESULFAME POTASSIUM
9	ANHYDROUS CITRIC ACID
8	CARBOXYMETHYLCELLULOSE SODIUM
8	CELLULOSE, MICROCRYSTALLINE
2	D&C RED NO. 33

Last updated: November 8, 2026

Children's ibuprofen oral suspension is a mature OTC category with limited active-ingredient differentiation and meaningful opportunities in excipient design, dosing safety, taste, stability, packaging, and channel positioning. The strongest commercial concepts are alcohol-free, sugar-free or low-sugar suspensions with improved ibuprofen taste masking, reliable redispersibility, age-appropriate dosing devices, and packaging designed to reduce medication errors.

Children's Ibuprofen Oral Suspension: Excipient Strategy, Patent Position, and Commercial Opportunities

What is the commercial profile of children's ibuprofen oral suspension?

Children's ibuprofen oral suspension is an over-the-counter analgesic and antipyretic product generally marketed at 100 mg ibuprofen per 5 mL. It is used for temporary reduction of fever and relief of minor aches and pains in children and adults who can use the pediatric liquid dosage form.

The category is mature. The active pharmaceutical ingredient is widely available, the core indication is established, and many products compete through retail price, flavor, packaging, dosing convenience, and retailer distribution rather than through new clinical claims.

Product characteristic	Typical market position
Active ingredient	Ibuprofen
Common strength	100 mg/5 mL
Dosage form	Oral suspension
Regulatory category	OTC analgesic and antipyretic
Primary users	Children, caregivers, pediatric households
Core indications	Fever and minor aches and pains
Primary competitors	Brand, store-brand, supermarket, pharmacy, and e-commerce products
Key differentiation factors	Taste, excipients, dose accuracy, packaging, price, preservative profile
Main technical risks	Poor taste, sedimentation, caking, microbial growth, dosing errors
Main commercial risks	Price erosion, retailer substitution, brand loyalty, seasonal demand

Children's Motrin and Advil Children's are well-known branded examples. Private-label products compete at substantially lower prices and often use similar strengths and dosage instructions. FDA labeling generally permits use in children six months and older, subject to product labeling and age or weight-based dosing instructions. Infants younger than six months should not be treated without medical direction. (FDA, 2022a; DailyMed, 2024a)

Which excipients are used in children's ibuprofen suspension?

The excipient system normally contains a vehicle, suspending agent, sweetener, flavor, buffer, preservative or preservation system, wetting agent, and viscosity modifier. Exact compositions vary by manufacturer and may change by product, market, and manufacturing site.

Common excipient classes include:

Excipient function	Representative materials	Formulation purpose
Vehicle	Purified water	Continuous phase
Suspending agent	Microcrystalline cellulose with carboxymethylcellulose sodium, xanthan gum, or related polymers	Keeps ibuprofen particles dispersed
Sweetener	Sucrose, sorbitol, sucralose, saccharin sodium, or combinations	Masks bitterness and improves acceptance
Flavor	Cherry, berry, grape, orange, or other flavors	Reduces medicinal taste
Wetting agent	Polysorbate or other surfactant	Improves particle wetting and dispersion
Buffer	Citric acid, sodium citrate, phosphate, or related systems	Controls pH and supports stability
Preservative	Sodium benzoate, benzoic acid, parabens, or other permitted systems	Controls microbial growth
Chelating agent	Disodium edetate	May improve preservative performance and oxidative stability
Viscosity modifier	Cellulose derivatives, gums, polyols	Controls sedimentation and pour behavior
Antifoaming agent	Silicone-based or other permitted materials	Reduces foam during manufacturing and dosing

The FDA Inactive Ingredient Database is a useful benchmark for excipient precedent, but it does not establish that every listed excipient is appropriate for every pediatric formulation, concentration, route, or age group. Sponsors must evaluate the complete formulation and pediatric exposure. (FDA, 2024a)

What excipient strategy best improves pediatric performance?

The most valuable strategy is a balanced suspension system that produces rapid redispersion without creating excessive pour resistance. A formulation that remains suspended but requires forceful shaking or pours slowly can increase caregiver dosing errors.

Taste masking

Ibuprofen has a strong, persistent bitter and medicinal taste. Flavor alone is often insufficient. A practical taste-masking strategy combines:

1. A sweetener system with immediate and lingering sweetness.
2. A high-impact flavor compatible with the target market.
3. Particle-size control or coating of ibuprofen.
4. pH adjustment within the acceptable stability and tolerability range.
5. Reduction of surfactant-related bitterness.
6. Sensory testing in the intended pediatric age range, where ethically and operationally appropriate.

Sorbitol can contribute sweetness and body without the sucrose load of a conventional syrup. Sucralose or saccharin sodium can provide high-intensity sweetness at low concentration. Polyols may create gastrointestinal concerns at excessive exposure, so the total daily dose and dosing frequency require review.

A low-sugar formulation can target households seeking reduced sugar, while a sucrose-containing product may deliver a more familiar syrup profile and lower raw-material cost. The commercial choice depends on sensory performance, claims strategy, and retailer positioning.

Suspension and redispersibility

Ibuprofen is poorly water-soluble, so the product must maintain a uniform dispersion. The suspension system should provide:

• Rapid redispersion after storage.
• Low sedimentation during normal use.
• Minimal caking.
• Consistent dose concentration from the first to the last dose.
• Acceptable syringe and cup delivery.
• A pour profile that does not create drips or uncontrolled flow.

Microcrystalline cellulose and carboxymethylcellulose combinations are established suspension platforms. Xanthan gum can support viscosity and suspension stability but may create undesirable stringiness or slower syringe delivery. A mixed polymer system often provides better control than relying on a single thickener.

The formulation should be evaluated after temperature cycling, long-term storage, agitation, transport simulation, and repeated opening. A product that passes initial viscosity testing but forms a hard sediment during storage has limited commercial value.

Preservative selection

Aqueous pediatric suspensions are vulnerable to microbial contamination after opening. Preservatives must be selected against the product's pH, packaging, manufacturing process, microbial challenge results, and excipient compatibility.

Sodium benzoate and benzoic acid systems are commercially familiar. Parabens may provide broad preservation but can create labeling, consumer-perception, or compatibility concerns. A preservative-free presentation may be attractive but generally requires stronger microbiological controls, a single-dose or unit-dose package, or a validated multidose delivery system that limits contamination.

A preservative-free multidose bottle is not automatically a superior product. It requires evidence that the container, closure, dosing device, opening pattern, and formulation together maintain microbiological quality through the labeled in-use period.

What formulations are protected by intellectual property?

The ibuprofen active ingredient is long off patent. Core composition claims covering a conventional 100 mg/5 mL ibuprofen suspension are difficult to defend unless they include a specific and non-obvious combination of excipients, particle engineering, delivery technology, or measurable performance.

Potentially protectable formulation concepts include:

• Coated or encapsulated ibuprofen particles that reduce bitterness.
• Specific polymer combinations that improve redispersion and dose uniformity.
• Preservative-free multidose suspensions with specialized packaging.
• Unit-dose sachets or stick packs.
• Formulations with defined particle-size distributions.
• Stable systems with reduced sedimentation and controlled viscosity.
• Pediatric formulations with a particular pH, flavor, and sweetener combination.
• Metered oral dosing systems that reduce dose variability.
• Manufacturing processes that produce a defined suspension microstructure.

Patent strength depends on claim breadth and reproducibility. A claim limited to common excipients at conventional concentrations is vulnerable to obviousness and design-around arguments. A stronger position generally requires a defined technical result, such as improved taste scores, lower sedimentation, faster redispersion, improved microbial robustness, or reduced dosing variability.

IP category	Likely strength for a new entrant	Commercial relevance
Ibuprofen composition of matter	None for ordinary ibuprofen	Low
Conventional 100 mg/5 mL suspension	Low	Low
Specific taste-masking technology	Moderate to high if supported by data	High
Novel excipient combination	Moderate	Moderate to high
Specialized container or dosing system	Moderate	High
Manufacturing process	Moderate	Moderate
Flavor alone	Low	Moderate
Packaging design	Low to moderate	High for brand differentiation
Trade secret process controls	Potentially meaningful	Moderate

What is the FDA regulatory status of children's ibuprofen suspension?

The category is regulated as an OTC analgesic and antipyretic. FDA's OTC monograph framework identifies permitted active ingredients, indications, directions, warnings, and conditions for marketing without an individual product approval when the product complies with the applicable monograph and other requirements. FDA's internal analgesic monograph identifies ibuprofen as an active ingredient for temporary relief of minor aches and pains and reduction of fever. (FDA, 2022a)

A company may also commercialize a product through an approved drug application, including an abbreviated new drug application where the reference product and regulatory pathway support that approach. The regulatory route affects labeling, product-specific requirements, Orange Book visibility, and the scope of potential patent certifications.

Key regulatory issues include:

• Pediatric dosing by age and weight.
• Concentration clarity, especially where multiple ibuprofen liquids are sold.
• Measuring-device accuracy.
• Safety warnings for gastrointestinal bleeding, allergic reactions, kidney risk, and dehydration-related use.
• Container closure integrity.
• Microbial limits and preservative effectiveness.
• Stability after opening.
• Labeling for shaking before use.
• Child-resistant packaging.
• Compliance with current good manufacturing practice requirements.

What is the Orange Book status of children's ibuprofen oral suspension?

There is no single Orange Book status for the entire children's ibuprofen oral suspension category. Orange Book treatment depends on the specific approved application, reference listed drug, dosage form, strength, and marketing status.

OTC monograph products do not depend on a conventional branded NDA patent estate in the same way as a prescription product approved through an NDA. An approved application may have Orange Book records, while a monograph-compliant product may be marketed without relying on an Orange Book-listed patent position.

The practical implication is that a generic or private-label entrant may face less patent risk than in a prescription product category, but it still must address:

• Regulatory pathway selection.
• Reference product or monograph compliance.
• Formulation equivalence where required.
• Bioavailability or comparative requirements, if applicable.
• Manufacturing and quality standards.
• Trademark and trade dress restrictions.
• Product liability and pediatric safety exposure.

When does children's ibuprofen lose exclusivity?

The core ibuprofen molecule has no remaining meaningful composition-of-matter exclusivity. Traditional patent barriers to a conventional pediatric suspension have expired. Market exclusivity is therefore commercial rather than molecule-based.

The relevant barriers are usually:

Barrier	Current importance
Core active-ingredient patent	Minimal
Basic formulation patent	Low unless technically specific
Regulatory exclusivity	Limited for a mature OTC ingredient
Brand recognition	Moderate
Retail shelf placement	High
Pediatric taste acceptance	Moderate to high
Manufacturing scale	Moderate
Packaging and dosing system	Moderate
Seasonal inventory and logistics	Moderate

Paragraph IV challenges are generally relevant to patent-listed approved drug applications, not to ordinary monograph-based OTC entry. A company pursuing an ANDA against a listed reference product could face certification and litigation issues if relevant patents are listed. A monograph-compliant product may not present the same Paragraph IV profile.

How strong is the patent estate for a new ibuprofen suspension?

A new suspension can create a defensible position, but the strongest protection is usually narrow and product-specific.

Stronger patent opportunities

A sponsor could pursue claims directed to a measurable formulation outcome, such as:

• A defined ibuprofen particle coating with sensory improvement.
• A suspension that redisperses within a specified time after storage.
• A formulation that maintains content uniformity across the dosing sequence.
• A preservative-free system with validated in-use microbial protection.
• A dosing package that limits dose delivery to a defined volume.
• A powder-for-reconstitution product with improved storage stability.
• A high-concentration pediatric formulation that reduces administration volume, if clinically and regulatorily acceptable.

Weaker patent opportunities

Claims limited to the following are less likely to provide durable protection:

• Cherry flavor added to a conventional suspension.
• A standard sweetener substitution.
• Common viscosity modifiers at routine levels.
• Conventional use of a 100 mg/5 mL concentration.
• Packaging color or generic bottle geometry.
• A broad list of excipients without demonstrated technical effect.

Trade secrets can complement patents. Mixing order, hydration time, homogenization conditions, particle-size control, deaeration, and fill-line parameters may materially affect product quality while remaining difficult for competitors to identify.

What commercial opportunities exist in children's ibuprofen suspension?

Premium taste and adherence products

A premium product can target caregivers who prioritize acceptance over lowest price. The value proposition should be supported by sensory data, not only flavor naming. Better taste may reduce refusal, spitting, and incomplete administration.

Sugar-free and low-sugar products

Sugar-free products can target consumers managing sugar intake, families concerned about dental exposure, and pharmacies seeking a differentiated private-label product. The formulation must control aftertaste and avoid excessive polyol loading.

Preservative-free presentations

Preservative-free products can occupy a premium niche if supported by suitable packaging. Unit-dose cups, sachets, or a validated contamination-resistant bottle can provide a credible product distinction.

High-concentration products

A higher concentration could reduce dose volume, but concentration changes increase medication-error risk. The label, dosing device, carton, and digital communication must clearly distinguish the product from 100 mg/5 mL competitors. A higher concentration should not be commercialized solely to reduce bottle size.

Better dosing systems

The most practical differentiation may be the dosing device. A low-dead-space oral syringe with clear graduations, an integrated bottle adapter, or a calibrated dosing cap can improve caregiver performance. Packaging claims should be based on human-factors testing.

E-commerce and subscription supply

Fever and pain products have recurring household demand, especially during respiratory illness seasons. E-commerce bundles can combine ibuprofen suspension with dosing syringes, thermometers, or age-specific care products. The company must avoid implying that combination products treat a disease beyond the permitted labeling.

Private-label manufacturing

Contract manufacturers can offer retailers a platform with multiple flavors, sugar profiles, bottle sizes, and packaging formats. Scale economics depend on access to validated suspension technology, reliable flavor supply, and seasonal production planning.

How does children's ibuprofen compare with children's acetaminophen?

Ibuprofen and acetaminophen compete directly in pediatric fever and pain relief, but the excipient and labeling strategies differ.

Factor	Ibuprofen suspension	Acetaminophen suspension
Typical pediatric concentration	100 mg/5 mL	Commonly 160 mg/5 mL
Taste challenge	Strong bitterness and medicinal persistence	Also bitter, with different flavor profile
Main formulation challenge	Suspension stability and taste masking	Taste masking and concentration control
Typical use limitation	Generally labeled for six months and older	Often labeled for younger infants, subject to product directions
Key safety concerns	Gastrointestinal, renal, allergic, dehydration-related risks	Liver toxicity and duplicate acetaminophen exposure
Differentiation opportunity	Redispersion, taste, preservative profile, dosing device	Dose safety, taste, concentration clarity, combination-use education

A dual-brand portfolio can capture both ingredients, but the products require separate labeling, safety communication, and human-factors controls. The company should not encourage alternating products without appropriate medical guidance.

What manufacturing and IP barriers affect market entry?

Manufacturing barriers are moderate rather than extreme. A competent liquid-dose manufacturer can produce the product, but commercial reliability requires control over:

• Ibuprofen particle size and wetting.
• Polymer hydration.
• Suspension uniformity during filling.
• Fill-volume accuracy.
• Flavor and sweetener variability.
• Microbial control.
• Preservative effectiveness.
• Bottle and closure compatibility.
• In-use stability.
• Dosing-device performance.

Scale-up is a significant risk. A formulation that performs well in a laboratory vessel may show different viscosity, foaming, air entrapment, or suspension behavior in commercial equipment. Process parameters should be treated as part of the product strategy, not only as manufacturing details.

What generic launch scenarios exist?

Low-cost store-brand launch

This scenario uses a conventional 100 mg/5 mL suspension, standard bottle, familiar flavor, and low-cost excipients. It competes on price and retail distribution. Patent exposure is generally low, but margins are compressed.

Premium formulation launch

This scenario uses improved taste masking, sugar-free positioning, a high-quality syringe, and differentiated packaging. It requires stronger sensory and human-factors evidence but can support a higher retail price.

Preservative-free launch

This scenario uses unit-dose or contamination-resistant packaging. Packaging cost and supply complexity increase, but the product can target premium pediatric and specialty channels.

Platform licensing launch

A technology owner can license taste-masked ibuprofen particles, a suspension platform, or a dosing package to a branded manufacturer or retailer. Royalty economics depend on whether the technology creates measurable consumer preference or reduces manufacturing cost.

What licensing deals are commercially plausible?

Licensing opportunities are most credible in four areas:

1. Taste-masked ibuprofen particles.
2. Proprietary suspension and redispersion technology.
3. Child-resistant or contamination-resistant dosing packaging.
4. Human-factors-tested dosing systems.

A formulation license is more valuable when it includes manufacturing know-how, scale-up data, stability data, and regulatory documentation. A patent license without transfer of process knowledge may have limited value because conventional excipient systems are readily available.

Potential licensees include branded OTC companies, retail pharmacy chains, consumer-health businesses, and contract manufacturers with pediatric liquid capacity.

What revenue exposure exists in this category?

Revenue is exposed to seasonality, private-label substitution, retailer bargaining power, and promotional pricing. Demand typically rises during periods of pediatric respiratory illness and fever, but sales do not remain constant throughout the year.

The most important revenue drivers are:

• Retail distribution and shelf placement.
• Brand or private-label status.
• Bottle size and unit economics.
• Flavor acceptance.
• Repeat purchase.
• E-commerce availability.
• Supply continuity during seasonal peaks.
• Product claims permitted by the regulatory pathway.

A differentiated excipient strategy can support pricing only if it produces a visible consumer benefit. Taste, dose accuracy, and reduced administration volume are more commercially persuasive than a technical ingredient list.

Key Takeaways

• Children's ibuprofen oral suspension is a mature OTC category with little core molecule patent risk.
• The standard commercial strength is commonly 100 mg/5 mL.
• The best excipient opportunities are taste masking, rapid redispersion, low-sugar or sugar-free design, preservative reduction, and dosing-device integration.
• Conventional excipient combinations alone provide weak patent protection.
• Stronger IP may cover coated ibuprofen particles, defined suspension performance, specialized packaging, or validated dosing systems.
• Orange Book and Paragraph IV risk depend on the specific regulatory route and application, not on the category as a whole.
• Private-label and branded products compete primarily through price, flavor, packaging, availability, and retailer access.
• Manufacturing scale-up, microbial control, and dose uniformity are major execution risks.
• Premium products need sensory, stability, microbiological, and human-factors evidence.
• The strongest licensing opportunities involve taste masking, dosing technology, and proprietary manufacturing know-how.

FAQs about children's ibuprofen oral suspension

Can a sugar-free ibuprofen suspension be commercially differentiated?

Yes. Sugar-free positioning can support a premium product, but the formulation must overcome polyol-related aftertaste, gastrointestinal tolerance concerns, and the absence of sucrose body. Sensory testing is essential.

Is a preservative-free ibuprofen suspension feasible?

Yes, but the packaging and in-use microbiological strategy must support the claim. Unit-dose packaging is simpler than a conventional multidose bottle.

Does a new flavor create meaningful patent protection?

Usually not. Flavor claims are generally weak unless combined with a technically defined formulation that produces an unexpected sensory or stability result.

Is a higher-strength ibuprofen suspension commercially attractive?

It can reduce administration volume and bottle size, but it increases medication-error risk. The product requires clear concentration labeling, a calibrated dosing device, and human-factors validation.

Can a company launch a private-label product without a Paragraph IV challenge?

Often, if the product is marketed under the applicable OTC monograph and does not rely on an infringing listed patent. The exact answer depends on the selected regulatory route, reference product, and any applicable Orange Book-listed patents.

References

1. DailyMed. (2024a). Children's ibuprofen oral suspension labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2022a). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2024a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. U.S. Food and Drug Administration. (2022b). Dosage delivery devices for orally administered liquid drug products. Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dosage-delivery-devices-orally-administered-liquid-drug-products

6. U.S. Food and Drug Administration. (2023b). Drug products marketed in the United States that contain ibuprofen. FDA Drug Database resources. https://www.fda.gov/drugs/industrial-medical-and-specialty-use-drugs/drug-products-containing-ibuprofen